303 related articles for article (PubMed ID: 16157900)
1. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
4. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
5. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Polman C; Barkhof F; Sandberg-Wollheim M; Linde A; Nordle O; Nederman T;
Neurology; 2005 Mar; 64(6):987-91. PubMed ID: 15781813
[TBL] [Abstract][Full Text] [Related]
6. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
7. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
12. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
[TBL] [Abstract][Full Text] [Related]
13. Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.
Moraal B; van den Elskamp IJ; Knol DL; Uitdehaag BM; Geurts JJ; Vrenken H; Pouwels PJ; van Schijndel RA; Meier DS; Guttmann CR; Barkhof F
Ann Neurol; 2010 May; 67(5):667-75. PubMed ID: 20437564
[TBL] [Abstract][Full Text] [Related]
14. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
15. Immunological studies of mitoxantrone in primary progressive MS.
Pelfrey CM; Cotleur AC; Zamor N; Lee JC; Fox RJ
J Neuroimmunol; 2006 Jun; 175(1-2):192-9. PubMed ID: 16644023
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.
Correale J; Rush C; Amengual A; Goicochea MT
J Neuroimmunol; 2005 May; 162(1-2):173-83. PubMed ID: 15833373
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
19. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
Minneboo A; Uitdehaag BM; Ader HJ; Barkhof F; Polman CH; Castelijns JA
Neurology; 2005 Jul; 65(1):56-61. PubMed ID: 16009885
[TBL] [Abstract][Full Text] [Related]
20. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]